aganirsen

DRUG2 trials

Sponsors

Laboratoires Kol, Gene Signal SAS

Conditions

Ischaemic Central Retinal Vein OcclusionNeovascular GlaucomaWet Age-Related Macular Degeneration (wAMD) Patients

Phase 2

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

Gene Signal SASIschaemic Central Retinal Vein Occlusion, Neovascular Glaucoma

Start: 2017-01-31End: 2019-12-31Target: 333Updated: 2016-10-31

A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study

Not yet recruitingCTIS2026-526775-27-00

Laboratoires KolWet Age-Related Macular Degeneration (wAMD) Patients

Target: 162Updated: 2026-08-10

Related Papers

A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma – the STRONG study: study protocol for a randomised controlled trial

Trials2017-03-1616 citations